TuHURA Biosciences Q3 2026: Cash $1.9M, R&D Falls to $3.7M

TuHURA Biosciences, Inc. (NASDAQ: HURA) reported third quarter 2026 financial results on 13 November 2026, disclosing cash and cash equivalents of $1.9 million at September 30, 2026, and research and development expenses of $3.7 million for the quarter, down $1.3 million from $5.0 million a year earlier. The Tampa-based Phase 3 immuno-oncology company said it drew $5.6 million from a $50 million credit facility with its largest shareholder, Parkview, during the quarter, contributing to $9.2 million in gross proceeds received on that facility as of September 30.

Context — Why TuHURA's Q3 2026 Cash Position Matters Now

The company's cash balance of $1.9 million sits against a $50 million credit facility from its largest shareholder, which TuHURA describes as non-dilutive financing. That framing matters for a clinical-stage biotech: the facility lets the company fund operations without issuing new equity, preserving the value of its roughly 65.8 million common shares outstanding at September 30, 2026.

The trigger for the quarter's disclosures is a cluster of regulatory and clinical events. In October, TuHURA said it received FDA clearance for a Phase 1b study of TBS-2025, its VISTA-inhibiting antibody, in relapsed or refractory mutated NPM1 acute myeloid leukemia. The company also announced three poster presentations at the 68th American Society of Hematology Annual Meeting, scheduled for December 12-15, 2026 in New Orleans.

Those events build on earlier milestones. TuHURA has initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 as an adjunctive therapy to Keytruda (pembrolizumab) in first-line advanced or metastatic Merkel Cell Carcinoma. The company also reported preliminary data from an open-label front-line study of IFx-2.0 with Keytruda in deep-seated metastatic MCC, showing major objective partial responses in the first three patients, all ongoing for more than six months.

CEO Dr. James Bianco said the company continues to make progress across each program, citing the FDA collaboration on TBS-2025 and the durability of the IFx-2.0 responses. The company did not disclose the interest rate, maturity, or covenants attached to the Parkview facility.

Data — What the Q3 2026 Numbers Show

R&D spending fell to $3.7 million from $5.0 million year over year. TuHURA attributed the $1.3 million decrease to lower manufacturing costs, which it expects to resume in the next quarter with the start of the TBS-2025 clinical trial material manufacturing campaign. General and administrative expenses rose to $2.0 million from $1.6 million, a $0.4 million increase the company tied to non-cash stock compensation and public-company costs.

Metric	Q3 2026	Q3 2025
R&D expense	$3.7M	$5.0M
G&A expense	$2.0M	$1.6M
Cash and equivalents	$1.9M	not disclosed

For the nine months ended September 30, 2026, net cash used in operating activities was $18.1 million, compared with $22.1 million in the prior-year period. Net cash provided by financing activities was $16.5 million, up from $13.4 million a year earlier. The financing increase reflects the Parkview credit facility drawdowns.

Shares outstanding stood at approximately 65.8 million at September 30, 2026. The company did not provide a per-share loss figure in the release, nor did it disclose revenue, as it remains a clinical-stage operation without approved products. TuHURA also did not give a cash runway estimate in the report.

Analysis — What TuHURA's Pipeline Means for Biotech Investors

The cash position of $1.9 million is thin relative to the $3.7 million quarterly R&D burn, but the $50 million Parkview facility changes the liquidity picture. With $9.2 million drawn as of September 30 and $5.6 million of that in Q3 alone, the facility is the company's primary funding mechanism. Whether TuHURA can continue drawing depends on terms it has not disclosed.

The clinical catalysts are the real driver. The IFx-2.0 Phase 3 trial in Merkel Cell Carcinoma targets a rare skin cancer with limited treatment options. The preliminary data from three patients showing responses lasting more than six months is early but directionally positive. The TBS-2025 program in mutated NPM1 AML addresses a molecularly defined subgroup representing approximately 35% of AML patients, according to the company.

A counter-argument: three patients is a very small sample. The open-label design has no control arm, so the durability of responses cannot be attributed to IFx-2.0 with statistical confidence. The company acknowledged the early stage by calling the results a "first look."

The intellectual property buildout is a second-order positive. TuHURA received a U.S. patent broadening coverage for TBS-2025 to include bispecific and multi-specific antibodies across all human antibody classes, with methods of treatment extending into autoimmune disease and infection. The patent term runs to 2042. A separate patent covers DOR Antibody Drug Conjugate technology through 2043. Those dates assume no patent term adjustment or regulatory extension.

Positioning: the stock trades on clinical readouts, not quarterly financials. Investors long the name are effectively long the IFx-2.0 Phase 3 and TBS-2025 Phase 1b data. The non-dilutive facility reduces near-term dilution risk, which is the primary concern for micro-cap biotech holders.

Outlook — What to Watch for TuHURA in 2026 and 2027

The company laid out a milestone schedule by program. For IFx-2.0, TuHURA expects orphan drug designation in MCC in the second half of 2026, preliminary results from the front-line study with Keytruda when administered by CT or ultrasound-guided techniques to metastatic deep-seated MCC in the first half of 2027, and completion of enrollment in the Phase 3 registrational study in the second half of 2027.

For TBS-2025, the company expects to initiate a Phase 1b/2 trial in mutated NPM1 relapsed/refractory AML in the second half of 2026, receive orphan drug designation in AML in the first half of 2027, and report preliminary safety and response data in the first half of 2027. For its MDSC inhibitor bi-specific ADCs, TuHURA expects ASH presentations and initiation of in vivo proof-of-concept studies, both in the second half of 2026.

The ASH meeting on December 12-15, 2026 is the nearest catalyst. The company said the scientific review committee recognized the importance of its DOR discoveries in controlling MDSC proliferation, recruitment, and immunosuppressive capabilities. No price levels or technical thresholds were provided in the report.

Frequently Asked Questions

What does TuHURA's $1.9 million cash balance mean for retail investors?

A $1.9 million cash balance is low for a clinical-stage biotech, but TuHURA has access to a $50 million credit facility from its largest shareholder, Parkview. The company drew $5.6 million in Q3 2026 and had received $9.2 million in gross proceeds as of September 30. The facility is described as non-dilutive, meaning it does not involve issuing new shares. However, the company did not disclose the facility's interest rate, maturity, or covenants.

Why did TuHURA's R&D expenses fall in Q3 2026?

R&D expenses fell to $3.7 million from $5.0 million year over year, a $1.3 million decrease. TuHURA attributed the drop to lower manufacturing costs. The company said those costs are expected to resume in the next quarter with the start of the TBS-2025 clinical trial material manufacturing campaign. That means the Q3 decline is timing-related, not a permanent reduction in spending, and investors should expect R&D to rise again.

What is the next catalyst for TuHURA stock?

The nearest catalyst is the 68th American Society of Hematology Annual Meeting on December 12-15, 2026 in New Orleans, where TuHURA will present three posters on its Delta Opioid Receptor technology. Beyond that, the company expects to initiate a Phase 1b/2 trial of TBS-2025 in mutated NPM1 relapsed/refractory AML in the second half of 2026 and to receive orphan drug designation for IFx-2.0 in Merkel Cell Carcinoma in the same period.

Bottom Line

TuHURA's $1.9 million cash balance is offset by a $50 million non-dilutive facility, leaving clinical data as the sole near-term value driver.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.